Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF ... which big pharma buyers would need to offer as much as $60 billion to gain traction ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

EMA clears Vertex' Symkevi + Kalydeco for cystic fibrosis in children aged 6-11, the first disease-modifying therapy patients in this age group with two F508del mutations or one F508del and a ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

On March 7, 2025, Vertex Pharmaceuticals announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its ...

Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

In March 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the safety, and tolerability and efficacy ...

The genetic condition cystic fibrosis had no treatments on the NHS before 2019 and a Daily Express campaign - now a miracle ...

Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX).The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...